154 related articles for article (PubMed ID: 31249529)
1. How Changes in Reimbursement Practices Influence the Financial Sustainability of Medicine Policy: Lessons Learned from Slovakia.
Tesar T; Obsitnik B; Kaló Z; Kristensen FB
Front Pharmacol; 2019; 10():664. PubMed ID: 31249529
[No Abstract] [Full Text] [Related]
2. Potential Cost-Savings From the Use of the Biosimilars in Slovakia.
Tesar T; Golias P; Kobliskova Z; Wawruch M; Kawalec P; Inotai A
Front Public Health; 2020; 8():431. PubMed ID: 32974261
[No Abstract] [Full Text] [Related]
3. The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia.
Tesar T; Golias P; Masarykova L; Kawalec P; Inotai A
Front Pharmacol; 2021; 12():795002. PubMed ID: 34966285
[No Abstract] [Full Text] [Related]
4. INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SLOVAKIA.
Tesar T; Hloska A; Wawruch M; Lehocka L; Snopkova M; Masarykova L
Int J Technol Assess Health Care; 2017 Jan; 33(3):345-349. PubMed ID: 28434416
[TBL] [Abstract][Full Text] [Related]
5. Drug Policy in Slovakia.
Bucek Psenkova M; Visnansky M; Mackovicova S; Tomek D
Value Health Reg Issues; 2017 Sep; 13():44-49. PubMed ID: 29073987
[TBL] [Abstract][Full Text] [Related]
6. Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors.
Linley WG; Hughes DA
Pharmacoeconomics; 2012 Sep; 30(9):779-94. PubMed ID: 22676385
[TBL] [Abstract][Full Text] [Related]
7. Critical assessment of belgian reimbursement dossiers of orphan drugs.
Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
[TBL] [Abstract][Full Text] [Related]
8. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
Kim ES; Kim JA; Lee EK
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
[TBL] [Abstract][Full Text] [Related]
9. Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.
Wallerstedt SM; Henriksson M
Br J Clin Pharmacol; 2018 Jun; 84(6):1146-1155. PubMed ID: 29381234
[TBL] [Abstract][Full Text] [Related]
10. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
11. The Checklist for Standard Methodological Requirements and Reporting of Economic Evaluation of Medicines in Slovakia.
Bucek Psenkova M; Hlavinkova L; Visnansky M; Grega D; Ondrusova M
Value Health Reg Issues; 2024 Jan; 39():14-19. PubMed ID: 37967490
[TBL] [Abstract][Full Text] [Related]
12. Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making.
Franken M; Nilsson F; Sandmann F; de Boer A; Koopmanschap M
Pharmacoeconomics; 2013 Sep; 31(9):781-97. PubMed ID: 23839699
[TBL] [Abstract][Full Text] [Related]
13. Time From Marketing Authorization to Reimbursement of Medicines in Greece After the Introduction of the Health Technology Assessment Process From July 2018 to April 2022.
Beletsi A; Stefanou G; Kourlaba G
Value Health Reg Issues; 2023 Jul; 36():58-65. PubMed ID: 37030032
[TBL] [Abstract][Full Text] [Related]
14. Integrating public preferences into national reimbursement decisions: a descriptive comparison of approaches in Belgium and New Zealand.
Leopold C; Lu CY; Wagner AK
BMC Health Serv Res; 2020 Apr; 20(1):351. PubMed ID: 32334579
[TBL] [Abstract][Full Text] [Related]
15. Drug Policy in the Czech Republic.
Skoupá J
Value Health Reg Issues; 2017 Sep; 13():55-58. PubMed ID: 29073989
[TBL] [Abstract][Full Text] [Related]
16. Patient advocacy group involvement in health technology assessments: an observational study.
Single A; Cabrera A; Fifer S; Tsai J; Paik JY; Hope P
Res Involv Engagem; 2021 Nov; 7(1):83. PubMed ID: 34823610
[TBL] [Abstract][Full Text] [Related]
17. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
Schey C; Milanova T; Hutchings A
Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
[TBL] [Abstract][Full Text] [Related]
18. Drug Policy in Estonia.
Mägi K; Lepaste M; Szkultecka-Dębek M
Value Health Reg Issues; 2018 Sep; 16():1-4. PubMed ID: 29529444
[TBL] [Abstract][Full Text] [Related]
19. Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe.
Vončina L; Strbad T; Fürst J; Dimitrova M; Kamusheva M; Vila M; Mardare I; Hristova K; Harsanyi A; Atanasijević D; Banović I; Bobinac A
Appl Health Econ Health Policy; 2021 Nov; 19(6):915-927. PubMed ID: 34553334
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
